Refractory Soft Tissue Sarcoma: Clinical Trials

3 trials for Refractory Soft Tissue Sarcoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed. 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 23Completed 3

Follow Refractory Soft Tissue Sarcoma: new trials by email Literature Review of Refractory Soft Tissue Sarcoma trials Research Report on Refractory Soft Tissue Sarcoma

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma
Phase 2CompletedNational Cancer Institute (NCI)232018-08-132026-04-03
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
Tazemetostat - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma
Phase 2CompletedNational Cancer Institute (NCI)202017-11-132026-04-13
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Olaparib - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
Phase 2CompletedNational Cancer Institute (NCI)62017-09-142024-12-11

Narrower conditions

Ependymoma (3)  ·  Glioma (3)  ·  Hepatoblastoma (3)  ·  Histiocytosis, Langerhans-Cell (3)  ·  Lymphoma, Non-Hodgkin (3)  ·  Medulloblastoma (3)  ·  Neuroblastoma (3)  ·  Neuroectodermal Tumors, Primitive, Peripheral (3)  ·  Osteosarcoma (3)  ·  Rhabdoid Tumor (3)  ·  Rhabdomyosarcoma (3)  ·  Sarcoma (3)  ·  Wilms Tumor (3)  ·  Central Nervous System Neoplasms (2)  ·  Familial ependymoma (2)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3)  ·  Female Urogenital Diseases (3)  ·  Female Urogenital Diseases and Pregnancy Complications (3)  ·  Genetic Diseases, Inborn (3)  ·  Hemic and Lymphatic Diseases (3)  ·  Histiocytosis (3)  ·  Immune System Diseases (3)  ·  Immunoproliferative Disorders (3)  ·  Kidney Diseases (3)  ·  Kidney Neoplasms (3)  ·  Lung Diseases (3)  ·  Lung Diseases, Interstitial (3)  ·  Lymphatic Diseases (3)  ·  Lymphoma (3)  ·  Lymphoproliferative Disorders (3)

Interventions

olaparib (1)  ·  palbociclib (1)  ·  tazemetostat (1)

Sponsors

National Cancer Institute (NCI) (3)

Countries

Puerto Rico (3)  ·  United States (3)

Top investigators

Julia Glade-Bender (1)  ·  Rajen Mody (1)  ·  Susan N Chi (1)

Results publications

PMID 31401903, PMID 38815151, PMID 39298716

NIH funding

U10CA180886 (3)